Approval of Elfabrio® provides an additional treatment option for those living with Fabry diseasePARMA, Italy and WOODBRIDGE, Ontario, Dec. 16,...
Approval of Elfabrio® provides an additional treatment option for those living with Fabry diseasePARMA, Italy and WOODBRIDGE, Ontario, Dec. 16,...
Approval of Elfabrio® provides an additional treatment option for those living with Fabry diseasePARMA, Italy and WOODBRIDGE, Ontario, Dec. 16,...
We remain on track to deliver year-over-year revenue growth and to generate positive adjusted EBITDA for the fiscal year HACKENSACK,...
A new multi-direction DWI sequence, the latest Swoop® system software, and the first advancement in Hyperfine’s Optive AI™ software, delivers...
BOSTON, Dec. 15, 2025 /PRNewswire/ -- Linus Health, an AI-driven brain health company pioneering early detection of cognitive impairment and...
GENEVA, SWITZERLAND / ACCESS Newswire / December 15, 2025 / MindMaze Therapeutics Holding SA (SIX:MMTX) (MindMaze Therapeutics or the Company)...
Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Dec. 12, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Scientists developed an antibody treatment that...
New Technology Platform Reduces Administrative Burden for Healthcare Providers NationwideTAMPA, Fla., Dec. 12, 2025 /PRNewswire/ -- BoomRx, a fast-growing national...
AUSTIN, Texas--(BUSINESS WIRE)--#CognitiveHealth--BrainCheck, the leading FDA Class II digital cognitive assessment and care platform, has been awarded a $500,000 SBIR...
Developing Healthcare and Intelligent Interaction Through Core Acoustic InnovationBEIJING, Dec. 11, 2025 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or...
Today, ZEISS marks 100 years of operation in the U.S., helping Americans improve lives and reach profound achievements by applying...
The FDA clearance of enVast redefines coronary thrombectomy treatment and further expands Vesalio's commercial platform.PLANO, Texas, Dec. 11, 2025 /PRNewswire/...
Collaboration aims to automate RNA and protein detection in 3D tissue specimens, reducing complexity and technical barriers.Innovation has the potential...
Vancouver, British Columbia--(Newsfile Corp. - December 11, 2025) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an...
EMBOLD data to serve as basis of efficacy and safety following discussion with the FDABOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE)...
Original Vitamin Patch Pioneer Introduces Comprehensive Dopamine Precursor Formula Backed by Clinical ResearchLas Vegas, NV, Dec. 11, 2025 (GLOBE NEWSWIRE)...
Antigen spreading was evaluated in a subset of Phase 2 patients to assess the ability of ELI-002 7P to broaden...
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease Results show, for...
CRB-913 was safe and well-tolerated across all doses studiedDaily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all...